risedronic acid has been researched along with Esophageal and Gastric Varices in 2 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Esophageal and Gastric Varices: Dilated blood vessels in the ESOPHAGUS or GASTRIC FUNDUS that shunt blood from the portal circulation (PORTAL SYSTEM) to the systemic venous circulation. Often they are observed in individuals with portal hypertension (HYPERTENSION, PORTAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The groups had not only comparable Model for End-stage Liver Disease score and esophageal varices degree, but also similar incidence of digestive adverse effects." | 2.90 | Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial. ( Caramori, CA; Lima, TB; Nunes, HRC; Qi, X; Romeiro, FG; Santos, LAA; Silva, GF, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, LAA | 2 |
| Lima, TB | 2 |
| de Carvalho Nunes, HR | 1 |
| Qi, X | 2 |
| Romeiro, FG | 2 |
| Nunes, HRC | 1 |
| Silva, GF | 1 |
| Caramori, CA | 1 |
2 trials available for risedronic acid and Esophageal and Gastric Varices
| Article | Year |
|---|---|
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial.
Topics: Bone Density; Bone Density Conservation Agents; Esophageal and Gastric Varices; Esophagitis; Gastroi | 2022 |
Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial.
Topics: Absorptiometry, Photon; Adult; Aged; Calcium; Esophageal and Gastric Varices; Female; Follow-Up Stud | 2019 |